Short- and long-term HRQOL issues following brachytherapy for prostate cancer

References

• Norderhaug I, Dahl O, Hoisaeter PA et al Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness. Eur. Ural 44(1), 4046 (2003).
   Google Scholar
• Hakenberg OW Wirth MP, Hermann T et al Recommendations for the treatment of localized prostate cancer by permanent interstitial brachytherapy. Ural Int.70(1), 15–20 (2003).
   Google Scholar
• Brandeis J, Pashos CL, Henning JM, Litwin MS. A nationwide comparison of the principal treatments for early stage prostate carcinoma. Cancer89,1792–1799 (2000).
   PubMed Web of Science ®Google Scholar
• Lee WR, Moughan J, Owen JB, Zelefsky MJ. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Cancer 98(9), 1987-1994 (2003).
   Google Scholar
• Lee R, Penson DE Treatment outcomes in localized prostate cancer: a patient-oriented approach. Sem. Uml. Oncol 20(1), 66–73 (2002).
   Google Scholar
• Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanagh W Brachytherapy for carcinoma of the prostate: techniques, patient selection and clinical outcomes. Semin. Radiat. Oncol 12(1), 81–94 (2002).
   Google Scholar
• Vicini FA, Martinez A, Hanks G et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 95(10), 2126–2135 (2002).
   PubMedGoogle Scholar
• Altwein J, Ekman P, Barry M et al How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg symposium. Urology49(4A), 66–76 (1997).
   Google Scholar
• Nag S, Ellis RJ, Merrick GS, Bahnson R, Wallner K, Stock R. American brachytherapy society recommendations for reporting morbidity after prostate brachytherapy. Int. J. Radiat. Oncol Phys. 54(2), 462–470 (2002).
   Google Scholar
• Peschel RE, Colberg JW. Surgery, brachytherapy and external-beam radiotherapy for early prostate cancer. Lancet Oncol 4,233–241(2003).
   PubMed Web of Science ®Google Scholar
• Peschel RE, Han S, Colberg J. Ultrasound guided transperineal implant (IMP) versus radical prostatectomy (RP) for early prostate cancer. Int. J. Radiat. Oncol Phys. 51 (Suppl. 1), 292 (2001).
   Google Scholar
• Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer 1 Sci. Am.5, 301–306 (1999).
   Google Scholar
• Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W Palladium-103 brachytherapy for prostate cancer. Int. J. Radiat. Oncol Biol. Phys. 46, 839–850 (2000).
   Google Scholar
• Critz FA, Williams WH, Levinson AK, Benton JB, Holladay CT, Schnell FJ. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J. Uml. 164,738–743 (2000).
   Google Scholar
• Pollack A, Zagars GK, Smith LG et al. Prelimanary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.' Clin. Oncol 18(23), 3904–3911 (2000).
   Google Scholar
• Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int. J. Radiat. Oncol Biol. fiyc. 41(3), 491–500 (1998).
   Google Scholar
• Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J. Uml. 167, 123–126 (2002).
   Google Scholar
• Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose—response study: results of a self-assessment questionnaire. Urology51, 991–997 (1998).
   PubMed Web of Science ®Google Scholar
• Hsu IC, Pickett B, Shinohara K, Krieg R, Roach M III, Phillips T Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation. Int. J. Radiat. Oncol Biol. Phys. 46(4), 851–858 (2000).
   Google Scholar
• Fossa SD, Moynihan C, Serbouti S. Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study. Support Cate Cancer 4,118–128 (1996).
   Google Scholar
• Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient? Br. Cancer57, 109–112 (1988).
   Google Scholar
• Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the Capsure database. J. Ural 159, 1988–1992 (1998).
   PubMed Web of Science ®Google Scholar
• Joly F, Brune D, Couette J-E et al Health- related quality of life and sequelae in patients treated with BT and external beam irradiation for localized prostate cancer. Ann. Oncol 9,751–757 (1998).
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, %liner KE, Ling CC et al Comparison of the 5-year outcome and mobidity of three-dimensional conformal radiotherapy versus transperineal permanent Iodine-125 implantation for early-stage prostatic cancer. J. Clin. Oncol 17(2), 517–522 (1999).
   Google Scholar
• Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal Iodine 125 implantation for stage T1/T2 prostatic carcinoma. J. Clin. Oncol 14(2), 449–453 (1996).
   Google Scholar
• Sommers SD, Ramsey SD. A review of quality of life evaluations in prostate cancer. PharmacoEconomics 16(2), 127–140 (1999).
   PubMedGoogle Scholar
• Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial BT int. J. Radiat. Oncol Biol. Phys. 51(3), 614–623 (2001).
   Google Scholar
• •Comprehensive prospective study with baseline measure giving information on short-term health-related quality of life (HRQOD issues in different treatment modalities.
   Google Scholar
• Lee WR, McQuellon RP, Harris- Henderson K, Case LD, McCullough DL. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int. J. Radiat. Oncol Biol. 46,77–81 (2000).
   Google Scholar
• Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma. An examination of treatment-related, demographic and psychosocial factors. Cancer 92(6), 1451–1459 (2001).
   Google Scholar
• Wei JT, Rodney LD, Sandler HM et al Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J. Clin. Oncol 20(2), 557–566 (2002).
   Google Scholar
• ••Detailed report of HRQOL afterdifferent treatment modalities including brachythrapy.
   Google Scholar
• Davis JW, Kuban DA, Lynch DF, Schellhammer PE Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J. Ural 166,947–952 (2001).
   PubMed Web of Science ®Google Scholar
• Litwin MS. Health related quality of life in older men without prostate cancer. J. Ural 161,1180–1184 (1999).
   PubMed Web of Science ®Google Scholar
• Sanchez-Ortiz RF, Broderick GA, Rovner ES, Wein AJ, Whittington R, Malkowicz SB. Erectile function and quality of life after interstitial radiation therapy for prostate cancer. Int. J. Impot. Res. 12 (Suppl. 3), 18–24 (2000).
   Google Scholar
• Litwin MS, McGuigan IKA. Accuracy of recall in health-related quality of life assessment among men treated for prostate cancer. J. Clin. Oncol 17(9), 2882–2888 (1999).
   Google Scholar
• Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL. Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study. Med. Cate 38(8), 847–857 (2000).
   Google Scholar
• Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following 1–125 prostate brachytherapy. kit. j Radiat. Oncol Biol. Phys. 56(4), 1085–1092 (2003).
   Google Scholar
• Brandeis JM, Litwin Ms, Bumison M, Reiter RE. Quality of life outcomes after BT for early stage prostate cancer. J. Ural 163,851–857 (2000).
   PubMed Web of Science ®Google Scholar
• Krupski T, Petroni GR, Bisonette EA, Theodorescu D. Quality of life comparison of radical prostatectomy and interstitial BT in the treatment of clinically localized prostate cancer. Umlogy55(5), 736–742 (2000).
   Google Scholar
• Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma. Cancer 91(11), 2046–2055 (2001).
   PubMedGoogle Scholar
• Egawa S, Shimura S, Irie A etal. Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn. I Clin. Oncol 31(11), 541–547 (2001).
   Google Scholar
• Bacon CG, Giovannuci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J. Ural 166, 1804–1810 (2001).
   PubMed Web of Science ®Google Scholar
• Merrick GS, Butler WM, Galbreath RVV, Stipetich RL, Abel LJ, Lief JH. Erectile function after permanent prostate brachytherapy. kit. j Radiat. Oncol Biol. Phys. 52(4), 893–902 (2002).
   Google Scholar
• Merrick GS, Butler WM, %liner KE, Galbreath RVV, Lief JH. Long-term urinary quality of life after permanent prostate brachytherapy. kit. j Radiat. Oncol Biol. Phys. 56(2), 454–461 (2003).
   Google Scholar
• Merrick GS, Butler WM, Wanner KE et al. Dysuria after permanent prostate brachytherapy. kit. j Radiat. Oncol Biol. Phys. 55(4), 979–985 (2003).
   Google Scholar
• Stock RG, Stone NN, Iannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. kit.j Radiat. Oncol Biol. Phys. 35(2), 267–272 (1996).
   Google Scholar
• Arterbery VE, Frazier A, Dalmia P, Siefer J, Lutz M, Porter A. Quality of life after permanent prostate implant. Semin. Surg. Oncol 13,461–464 (1997).
   PubMedGoogle Scholar
• Merrick GS, Butler WM, Dorsey AT, Galbreath RVV, Blatt H, Lief JH. Rectal function following prostate brachytherapy. Int.j Radiat. Onto]. Biol. Phys. 48(3), 667–74 (2000).
   Google Scholar
• Blatt HJ, Abel LJ, Stipetich RL et al Utilization of a self-administered questionnaire to assess rectal function following prostate brachytherapy. Ufa NUI3: 21(5), 356–359 (2001).
   Google Scholar
• Potters L, Torre T, Feam PA, Leibel SA, Kattan MW Potency after permanent prostate BT for localized prostate cancer. Int.j Radiat. Onto]. Biol. Phys. 50(5), 1235–1242 (2001).
   Google Scholar
• Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J. Urol. 165, 436–439 (2001).
   Google Scholar
• Talcott JA, Clark JA, Stark PC, Mitchell SR Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J. Ural 166,494–499 (2001).
   PubMed Web of Science ®Google Scholar
• Henderson A, Laing RVV, Langley SEM. Quality of life following treatment for early prostate cancer: does low-dose rate (LDR) brachytherapy offer a better outcome? A Review. Eur Ural 45 (2), 134–141 (2004) .
   PubMedGoogle Scholar
• Potosky AL, Reeve BB, Clegg LX et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J. Natl Cancer Inst. 94(6), 430–436 (2002).
   PubMedGoogle Scholar
• Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.j Ural 163,1743–1746 (2000)
   PubMed Web of Science ®Google Scholar
• Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, Han M, Sanda MG. Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality of life outcome after prostate brachytherapy. Urology59 (4), 480–484 (2002).
   PubMedGoogle Scholar
• Brufsky A, Fontaine-Rothe P, Berlane K et al Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 49(6), 913–920 (1997).
   PubMedGoogle Scholar
• Miller NL, Bissonette EA, Bahnson R, Wilson J, Theodorescu D. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function and sexual function after prostate brachytherapy. Cancer 97(5), 1203–1210 (2003).
   PubMedGoogle Scholar
• Gotay CC. Quality of life assessment in cancer clinical research: current status and a look to the future. Expert Rev Pharmacoeconomics Outcomes Res. 3 (4), 479–486 (2003).
   Google Scholar